This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

TherapeuticsMD Phase 1 Pilot Study Shows TX-12-004-HR Estradiol VagiCap Improves Conditions Of Vulvar And Vaginal Atrophy (VVA)

Stocks in this article: TXMD

“Current estrogen therapies are antiquated. We are looking to leverage new technology to remove common and frustrating application and compliance issues related to legacy products. We believe the market is ripe for innovation and will grow significantly,” said Robert G. Finizio, Co-Founder and Chief Executive Officer of TherapeuticsMD.

The value of vaginally-administered estrogen therapy for women with moderate to severe VVA was recently re-affirmed in a 2013 Position Statement of The North American Menopause Society.

About the Study

This phase 1 pilot study sponsored by TherapeuticsMD was designed to evaluate the efficacy and safety of TX 12-004-HR in treating moderate to severe symptoms of VVA associated with menopause after 14 days of treatment, and to estimate the effect size and variability of VVA endpoints. Participants included 48 postmenopausal women (mean age 62.3 years) with at least one self-assessed symptom of vulvar and/or vaginal atrophy and meeting all other entry criteria were randomized in a 1:1 ratio to receive either TX 12-004-HR or a placebo VagiCap. Clinical evaluations were performed during the screening period at baseline (day 1 of the study) and on days 8 and 15. Serial blood samples for estradiol levels were collected on day 1 at 0, 1.0, 3.0 and 6.0 hours relative to administration of the first dose. Participants self-administered their assigned treatment intra-vaginally once daily at approximately the same time each morning. The primary efficacy analyses included all 48 women who completed the study.

Key findings of the study were evaluated by standard statistical methods and concluded that, as compared to the placebo group, women treated with TX 12-004-HR showed:

  • Statistically significant improvements in the Maturation index which included significant decreases in parabasal cells (p<0.0001);
  • Significant increases in superficial cells (p=0.0002) and in intermediate cells (p=0.0017);
  • Statistically significant decreases in vaginal pH (p=0.0002); and,
  • A significant reduction in the atrophic effects on epithelial integrity and vaginal secretions.

Although this study was not powered to demonstrate significant improvement in subjective symptoms such as vaginal dryness, irritation and pain during sexual activity, the treatment group demonstrated marginal improvement in the severity of these subjective symptoms.

2 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,461.32 -153.49 -0.92%
S&P 500 1,927.11 -14.17 -0.73%
NASDAQ 4,382.8470 -36.6310 -0.83%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs